A safety assessment of topical calcineurin inhibitors in the treatment of atopic dermatitis

MedGenMed Medscape General Medicine

Volumn 8, Issue 4, 2006, Pages

  Lebwohl, Mark ^a   Gower, Tara ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Embryon   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE VALERATE; CALCINEURIN INHIBITOR; CORTICOSTEROID; HYDROCORTISONE ACETATE; HYDROCORTISONE BUTYRATE; PIMECROLIMUS; TACROLIMUS; TRIAMCINOLONE ACETONIDE; CALCINEURIN; ENZYME INHIBITOR;

ADRENAL DISEASE; APPLICATION SITE ERYTHEMA; APPLICATION SITE PRURITUS; APPLICATION SITE REACTION; AREA UNDER THE CURVE; ATOPIC DERMATITIS; CLINICAL TRIAL; DAILY LIFE ACTIVITY; DISEASE CONTROL; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG LABELING; DRUG SAFETY; DRUG TOLERABILITY; FAMILY LIFE; FOOD AND DRUG ADMINISTRATION; HISTIOCYTOSIS; HUMAN; IMMUNE DEFICIENCY; LEUKEMIA; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MEDICAL ASSESSMENT; MEDICAL DECISION MAKING; MELANOMA; MOUSE; NONHODGKIN LYMPHOMA; NONHUMAN; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; SKIN ATROPHY; SKIN BURNING SENSATION; SKIN CANCER; SKIN INFECTION; STOMACH CANCER; THYROID CANCER; UNITED STATES; ANIMAL; DRUG ANTAGONISM; LEGAL ASPECT; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ANIMALS; CALCINEURIN; DERMATITIS, ATOPIC; DRUG LABELING; ENZYME INHIBITORS; HUMANS;

EID: 33749996464     PISSN: 15310132     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Leung DY, Bieber T. Atopic dermatitis. Lancet. 2003;361:151-160. Abstract
2. Kay J, Gawkrodger DJ, Mortimer MJ, Jaron AG. The prevalence of childhood atopic eczema in a general population. J Am Acad Dermatol. 1994;30:35-39. Abstract
3. Larsen FS, Hanifin JM. Epidemiology of atopic dermatitis. Immunol Allergy Clin North Am. 2002;22:1-24.
4. Rudikoff D, Lebwohl M. Atopic dermatitis. Lancet. 1998;351:1715-1721. Abstract
5. Ahuja A, Land K, Barnes CJ. Atopic dermatitis. South Med J. 2003;96:1068-1072. Abstract
6. Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol. 2001;10:11-18. Abstract
7. Beltrani VS, Boguneiwicz M. Atopic dermatitis. Dermatol Online J. 2003;9:1-27.
8. Leung DY, Bhan AK, Schneeberger EE, Geha RS. Characterization of the mononuclear cell infiltrate in atopic dermatitis using monoclonal antibodies. J Allergy Clin Immunol. 1983;71:47-56. Abstract
9. Hanifin JM, Cooper KD, Ho VC, et al. Guidelines of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology (AAD)/American Academy of Dermatology Association "Administrative Regulations for Evidence-Based Clinical Practice Guidelines." J Am Acad Dermatol. 2004;50:391-404.
10. Eichenfield LF. Consensus guidelines in diagnosis and treatment of atopic dermatitis. Allergy. 2004;59(suppl78):86-92.
11. Elidel [package insert]. East Hanover, NJ: Novartis Pharmaceuticals; 2006.
12. Protopic [package insert]. Deerfield, III: Astellas Pharma US, Inc.; 2006.
13. Breuer K, Werfel T, Kapp A. Safety and efficacy of topical calcineurin inhibitors in the treatment of childhood atopic dermatitis. Am J Clin Dermatol. 2005;6:65-77. Abstract
14. Alomar A, Berth-Jones J, Bos JD, et al. The role of topical calcineurin inhibitors in atopic dermatitis. Br J Dermatol. 2004; 151(suppl70):3-27.
15. Grassberger M, Baumruker T, Enz A, et al. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol. 1999; 141:264-273. Abstract
16. Hultsch T, Muller KD, Meingassner JG, Grassberger M, Schopf RE, Knop J. Ascomycin macrolactam derivative SDZ ASM 981 inhibits the release of granule-associated mediators and of newly synthesized cytokines in RBL 2H3 mast cells in an immunophilin-dependent manner. Arch Dermatol Res. 1998;290:501-507. Abstract
17. de Paulis A, Cirillo R, Ciccarelli A, de Crescenzo G, Oriente A, Marone G. Characterization of the anti-inflammatory effect of FK-506 on human mast cells. J Immunol. 1991;147:4278-4285. Abstract
18. Kapp A, Allen BR, Reitamo S. Atopic dermatitis management with tacrolimus ointment (Protopic). J Dermatolog Treat. 2003;14:5-16. Abstract
19. Hanifin JM, Ling MR, Langley R, Breneman D, Rafal E. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I, efficacy. J Am Acad Dermatol. 2001;44:S28-S38. Abstract
20. Paller A, Eichenfield LF, Leung DY, Stewart D, Appell M. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol. 2001;44:S47-S57. Abstract
21. Kang S, Lucky AW, Pariser D, Lawrence I, Hanifin JM. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol. 2001;44:S58-S64. Abstract
22. Chapman MS, Schachner LA, Breneman D, et al. Tacrolimus ointment 0.03% shows efficacy and safety in pediatric and adult patients with mild to moderate atopic dermatitis. J Am Acad Dermatol. 2005;53:S177-S185. Abstract
23. Boguniewicz M, Fiedler VC, Raimer S, Lawrence ID, Leung DY, Hanifin JM. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group. J Allergy Clin Immunol. 1998;102:637-644. Abstract
24. Reitamo S, Rustin M, Ruzicka T, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. J Allergy Clin Immunol. 2002;109:547-555. Abstract
25. Reitamo S, Van Leent EJ, Ho V, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. J Allergy Clin Immunol. 2002;109:539-546. Abstract
26. Eichenfield LF, Lucky AW, Boguniewicz M, et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol. 2002;46:495-504. Abstract
27. Wahn U, Bos JD, Goodfield M, et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics. 2002;110:e2.
28. Meurer M, Folster-Holst R, Wozel G, Weidinger G, Junger M, Brautigam M. Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. Dermatology. 2002;205:271-277. Abstract
29. Ho VC, Gupta A, Kaufmann R, et al. Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. J Pediatr. 2003;142:155-162. Abstract
30. Luger T, Van Leent EJ, Graeber M, et al. SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. Br J Dermatol. 2001;144:788-794. Abstract
31. Luger TA, Lahfa M, Folster-Holst R, et al. Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis. J Dermatolog Treat. 2004; 15:169-178. Abstract
32. Soter NA, Fleischer AB Jr, Webster GF, Monroe E, Lawrence I. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safety. J Am Acad Dermatol. 2001;44:S39-S46. Abstract
33. Reitamo S, Rissanen J, Remitz A, et al. Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial. J Invest Dermatol. 1998; 111:396-398. Abstract
34. Queille-Roussel C, Paul C, Duteil L, et al. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. Br J Dermatol. 2001;144:507-513. Abstract
35. American Academy of Dermatology Association Task Force. The use of topical calcineurin inhibitors in dermatology: safety concerns. Report of the American Academy of Dermatology Association Task Force. J Am Acad Dermatol. 2006;54:818-823. Abstract
36. Bieber T, Cork M, Ellis C, et al. Consensus statement on the safety profile of topical calcineurin inhibitors. Dermatology. 2005;211:77-78. Abstract
37. 37. Drug Regulatory Affairs. Elidel (pimecrolimus) Cream 1%. NDA 21-302 briefing document. Available at: http://www.fda.gov/ohrms/dockets/ac/05/ briefing/ 20054089b2_03_04-Elidel%20Novartis%20Briefing%20Bookredacted.pdf Accessed January 25, 2005.
38. Hultsch T, Kapp A, Spergel J. Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. Dermatology. 2005;211:174-187. Abstract
39. Harper J, Smith C, Rubins A, et al. A multicenter study of the pharmacokinetics of tacrolimus ointment after first and repeated application to children with atopic dermatitis. J Invest Dermatol. 2005;124:695-699. Abstract
40. Reitamo S, Wollenberg A, Schopf E, et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. The European Tacrolimus Ointment Study Group. Arch Dermatol. 2000; 136:999-1006. Abstract
41. Prograf [package insert]. Deerfield, III: Astellas Pharma US, Inc.; 2006.
42. US Food and Drug Administration, Pediatric Advisory Committee. Discussion Topic: Risk Evaluation, Labeling, Risk Communication, and Dissemination of Information on Potential Cancer Risk Among Pediatric Patients Treated for Atopic Dermatitis With Topical Dermatological Immunosuppressants. Rockville, Md: US Food and Drug Administration; 2005.
43. Van Leent EJ, Graber M, Thurston M, Wagenaar A, Spuls PI, Bos JD. Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis. Arch Dermatol. 1998; 134:805-809. Abstract
44. Thaci D, Steinmeyer K, Ebelin ME, Scott G, Kaufmann R. Occlusive treatment of chronic hand dermatitis with pimecrolimus cream 1% results in low systemic exposure, is well tolerated, safe, and effective. An open study. Dermatology. 2003;207:37-42. Abstract
45. Harper J, Green A, Scott G, et al. First experience of topical SDZ ASM 981 in children with atopic dermatitis. Br J Dermatol. 2001;144:781-787. Abstract
46. Allen BR, Lakhanpaul M, Morris A, et al. Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1% in atopic dermatitis patients. Arch Dis Child. 2003;88:969-973. Abstract
47. Fleischer AB Jr, Ling M, Eichenfield L, et al. Tacrolimus ointment for the treatment of atopic dermatitis is not associated with an increase in cutaneous infections. J Am Acad Dermatol. 2002;47:562-570. Abstract
48. Stiehm ER, Roberts RL, Kaplan MS, Corren J, Jaracz E, Rico MJ. Pneumococcal seroconversion after vaccination for children with atopic dermatitis treated with tacrolimus ointment. J Am Acad Dermatol. 2005;53:S206-S213. Abstract
49. Hofman T, Cranswick N, Kuna P, et al. Tacrolimus ointment does not affect the immediate response to vaccination, the generation of immune memory, or humoral and cell-mediated immunity in children. Arch Dis Child. 2006 June 23; [Epub ahead of print].
50. Papp KA, Werfel T, Folster-Holst R, et al. Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants and young children: a two-year study. J Am Acad Dermatol. 2005;52:240-246. Abstract
51. Papp KA, Breuer K, Meurer M, et al. Long-term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccination. J Am Acad Dermatol. 2005;52:247-253. Abstract
52. Jaracz E, Maher R, Simon D, Kristy R, Park S, Rico J. Safety profile of tacrolimus ointment: data from five years of post-marketing experience. Program and abstracts of the American Academy of Dermatology 64th Annual Meeting; March 3-7, 2006; San Francisco, California.
53. Fonacier L, Spergel J, Charlesworth EN, et al. Report of the topical calcineurin inhibitor task force of the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol. 2005;115:1249-1253. Abstract
54. Tran C, Lubbe J, Sorg O, et al. Topical calcineurin inhibitors decrease the production of UVB-induced thymine dimers from hairless mouse epidermis. Dermatology. 2005;211:341-347. Abstract
55. Yarosh DB, Pena AV, Nay SL, Canning MT, Brown DA. Calcineurin inhibitors decrease DNA repair and apoptosis in human keratinocytes following ultraviolet B irradiation. J Invest Dermatol. 2005;125:1020-1025. Abstract
56. Niwa Y, Terashima T, Sumi H. Topical application of the immunosuppressant tacrolimus accelerates carcinogenesis in mouse skin. Br J Dermatol. 2003; 149:960-967. Abstract
57. Food and Drug Administration. Protopic (tacrolimus) ointment. Center for Drug Evaluation and Research Application Number NDA 50777. 2005:1-51. Available at: http://www.fda.gov/cder/foi/nda/2000/50777_protopic.htm Accessed September 27, 2006.
58. Wijnen RM, Ericzon BG, Tiebosch AT, Buurman WA, Groth CG, Kootstra G. Toxicology of FK506 in the cynomolgus monkey: a clinical, biochemical, and histopathological study. Transpl Int. 1992;5(suppl1):S454-S458.
59. Cockerell CJ. American Academy of Dermatology. President's message: Elidel and Protopic alert. March 2005. Available at: http://www.aad.org/ aad/PresidentsMessage/ Accessed December 1, 2005.
60. Cockerell CJ. President's message: academy disappointed with restrictive new labeling for eczema medication, working to enhance dialogue with FDA. January 23, 2006; Available at: http://www.aad.org/professionals/ AdvocacyGovRelSkin/tci_information.htm Accessed June 1, 2006.